LEO Pharma's new drug study pulled before any volunteers enrolled
NCT ID NCT03995550
First seen May 05, 2026 · Last updated Jun 16, 2026 · Updated 7 times
Summary
This was an early-stage study designed to check the safety and tolerability of a new drug called LEO 142397 in healthy people. The study was planned in two parts: one group would get a single dose, and another would take it daily for two weeks. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Covance Clinical Research Unit Ltd.
Leeds, LS2 9LH, United Kingdom
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.